PDCD1 and melanoma: Despite their subdued migration pattern in vitro, PD-1high CAR-T cells exhibited greater accumulation and retention in melanoma tumors than their PD-1low counterparts in vivo and were more responsive to combination therapy with PD-1-targeting immune checkpoint blockade, helping to drive a potent early anti-tumor response.